Great company that is beginning to flounder. - Recensione dipendente - Dipendente anonimo presso AstraZeneca

4,0
14 feb 2017
Dipendente anonimo
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

The people are great. The greatest loss for me will be not working with my colleagues anymore.

Svantaggi

Pipeline falling short of expectation. Since losing the three largest contribution product patents, there has been little to make up for the loss. Diabetes portfolio is a performing poorly, Advair will soon be generic which means respiratory market will erode for Symbicort and the Oncology products -though innovative- can't make up the $$.

Esplora altre recensioni su AstraZeneca

5,0
25 giu 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Good products, great oncology pipeline

Svantaggi

Global leaders moving to US that have limited understanding of US environment

5,0
22 apr 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

I imagine this is very dependent on line management but I find my team and supervisors to be true champions of a high performing and highly compassionate work culture. I find my work challenging and rewarding, and have had opportunities to learn and grow and be rewarded and recognized for my output. No job is perfect but I’m truly happy to work here and at a time when AZ is truly rising like a rocket.

Svantaggi

Like any massive global corporate entity, things can sometimes move slowly and it can be challenging to navigate a high number of constantly evolving priorities and initiatives. That being said, AZ is very clear about its north stars and values which makes it possible to prioritize work that has the most impact and alignment with the company’s ambition and business prerogatives. 60% office attendance policy is also a bit funny when oftentimes I am on Teams calls with colleagues sitting in other areas of the world.

Vedi recensioni per: Utile|Valutazione|Data|Tutto